The Russian pharmaceutical market represents one of the most exciting investment opportunities available. In contrast to many areas of the world today, the Russian economy is booming, growing double digits, and expected to continue at this pace over the next decade. In fact, the CEBR World Economic League Table forecasts Russia to overtake most of the emerging markets by 2020, 4th only behind the US, China, and Japan.
This growth is being fueled by the Russian Government’s dedication to the maturing of the Pharma market through the implementation of a drug reimbursement system. The total Russian government health expenditures are expected US $0.8 trn - 0.96 trn per year.
One of the key steps in realising this vision was the formation of the collaboration between the Russian State owned venture capitalist group RUSNANO and the Amercian venture capital group Domain Accociates. The partners have committed to invest $760 Million in emerging life sciences technology companies. NovaMedica is key to this vision, formed to exclusively commercialize highly innovative products coming from this collaboration which have significant application for patient populations in Russia.
With many products set to move into NovaMedica from the Domain family of companies, we believe NovaMedica is uniquely positioned to facilitate innovative drug development and accelerate corporate growth. As the “partner of choice” for Russia, we are also open to a select group of corporate partnerships for those companies who wish to take advantage of this exciting, growing emerging market.
1. Cardiovascular
2. Orthopedics
3. Pediatrics/ Woman’s Health
4. GI
5. Ophthalmology
6. CNS
If you would like to discuss potential licensing opportunities, please contact us!
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024